| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1888 | |
| Phytochemical name or plant extracts | Withania somnifera extract | |
| PMID | 28090590 | |
| Literature evidence | These results warrant further studies to assess the underlying molecular mechanism of the anti-tumor activity of the WS extract in breast cancer. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Alcoholic extract | |
| Source of phytochemicals or plant Extracts | Withania somnifera | |
| Geographical availability | Afghanistan, Algeria, Angola, Assam, Bangladesh, Botswana, Burundi, Cameroon, Canary Is., Cape Provinces, Cape Verde, Chad, China North-Central, China South-Central, Cyprus, Djibouti, East Aegean Is., Egypt, Eritrea, Ethiopia, Free State, Greece, Gulf States, India, Iran, Kenya, Kriti, KwaZulu-Natal, Lebanon-Syria, Lesotho, Libya, Malawi, Mali, Mauritania, Morocco, Mozambique, Myanmar, Namibia, Niger, Nigeria, Northern Provinces, Oman, Pakistan, Palestine, Rwanda, Sardegna, Saudi Arabia, Sicilia, Sinai, Somalia, Spain, Sri Lanka, Sudan, Swaziland, Tanzania, Tunisia, Turkey, Uganda, West Himalaya, Yemen, Zambia, Zaïre, Zimbabwe | |
| Plant parts | Leaves and root | |
| Other cancers | Breast cancer | |
| Target gene or protein | CCL2, Caspase 3 | |
| Gene or Protein evidence | WS root extract inhibited proliferation of breast cancer cells in vitro and in vivo and significantly reduced expression of the cytokine, CCL2. Flow cytometry results showed that the extract arrested the cell cycle at S phase, and the increase in the caspase 3 activity suggested that the extract could induce cell apoptosis by a caspase mediated pathway. | |
| Target pathways | Caspase mediated pathway | |
| IC50 | 3.35 μg/ml against MCF-7 | |
| Potency | WS extract also inhibited proliferation of xenografted MDA-MB-231 cells. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, HCT116, HepH2, Transgenic (MMTV/Neu) mice | |
| Additional information | The WS extract reduced viability of MDA-MB-231 cells by 75% and 88% after exposure of the cells to 50 and 100 µg/mL, respectively, compared to vehicle-treated controls. WS extract caused a dose-dependent increase in the percentage of cells in the sub-G1 phase compared to untreated controls by 6% and 10% after exposure to 25 and 50 µg/mL WS extract, respectively. WS extract also inhibited proliferation of xenografted MDA-MB-231 cells. The WS extract caused reductions in xenograft size by 60% compared to the untreated control after 8 weeks of treatment. | |
| PubChem ID | NA | |
| Additional PMIDs | 27268658 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:821709-1 | |
| Safety | NA |